share_log

上海莱士:拟以42亿元收购南岳生物100%股权

Shanghai RAAS Blood Products plans to acquire 100% equity of Nanyue Bio for 4.2 billion yuan.

Breakings ·  Mar 26 13:48

Shanghai RAAS Blood Products announced that the company intends to acquire 100% equity of Nanyue Pharmaceutical Co., Ltd. through cash payment, where 87.9766% of the equity transfer consideration is 3.695 billion yuan, and 12.0234% of the equity transfer consideration is 0.505 billion yuan, totaling 4.2 billion yuan. After this Trade is completed, Nanyue Bio will become a wholly-owned subsidiary of Shanghai RAAS. Additionally, if Nanyue Bio's plasma collection volume reaches 305 tons in 2025, Shanghai RAAS will pay an additional 50 million yuan or have consideration.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 329

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.